Celtaxsys celtaxsys.com


Public list: Pharma Startups (6570) Rare Diseases (230)

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response.

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat...Show all

Company (Alive / Active)

Phone: 470-206-0153

Fax: 404-920-0701

201 17th Street
Suite 530
Atlanta, 30363
Georgia, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Celtaxsys $52.7M Jan 4, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Celtaxsys Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors

Competitors

Company Status Description Investors

VLST Corporation

Seattle, Washington, United States
Assets PurchasedVLST (Viral Logic Systems Technology) has developed a streamlined and efficient platform that rapidly yields biological therapeutic compositions of matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders. The VLST approach combines bioinformatics and proteomics to provide a rapid and rational approach to identifying new targets for the development of biologic therapies. Moreover, the process used to identify targets also provides ...Show allLogin to see details

Zafgen

Cambridge, Massachusetts, United States
IPO / Went publicZafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesit...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Inhibitors of leukotriene a4 hydrolase Sep 10, 2015 Jan 02, 2018 Patent
Inhibitors of leukotriene a4 hydrolase Sep 10, 2015 Nov 21, 2017 Patent
Methods of inhibiting leukotriene a4 hydrolase Sep 10, 2015 Nov 21, 2017 Patent
Inhibitors of leukotriene a4 hydrolase Sep 10, 2015 Oct 03, 2017 Patent
Chemorepulsion of cells Feb 02, 2010 Apr 11, 2017 Patent
See all 14 patents